Payment overview · 2025
General Payments
$724.18
32 reported records · 7 companies
Healthcare provider profile · identity verified
Sandeep Chandra, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BURBANK, IL · NPI 1063453876
Verified facts
What the public records show
CMS Open Payments records show Sandeep Chandra, M.D. received $724.18 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1406 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $306.01 | 42.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.61 | 18.7% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.26 | 16.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.20 | 8.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.01 | 7.6% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $25.78 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.31 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $724.18 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $234.96 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $121.26 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $108.52 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.55 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.20 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.20 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.01 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.01 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1406 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 154 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1406 | 124 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2494 | 385 |
| Eliquis | Apixaban | 1406 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 1384 | 212 |
| Gabapentin | Gabapentin | 1012 | 138 |
| Lisinopril | Lisinopril | 876 | 174 |
| Metoprolol Succinate | Metoprolol Succinate | 815 | 161 |
| Furosemide | Furosemide | 803 | 98 |
| Omeprazole | Omeprazole | 720 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 687 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 683 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 616 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 599 | 115 |
| Clopidogrel | Clopidogrel Bisulfate | 577 | 58 |
| Carvedilol | Carvedilol | 554 | 67 |
| Potassium Chloride | Potassium Chloride | 540 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 535 | 89 |
| Metformin Hcl | Metformin Hcl | 443 | 109 |
| Losartan Potassium | Losartan Potassium | 442 | 80 |
| Sertraline Hcl | Sertraline Hcl | 395 | 31 |
| Donepezil Hcl | Donepezil Hcl | 384 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 372 | 53 |
| Mirtazapine | Mirtazapine | 343 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 342 | 76 |
| Trazodone Hcl | Trazodone Hcl | 327 | 44 |
| Baclofen | Baclofen | 302 | 75 |
| Jardiance | Empagliflozin | 300 | 57 |
| Simvastatin | Simvastatin | 295 | 61 |
| Allopurinol | Allopurinol | 285 | 61 |
| Levetiracetam | Levetiracetam | 260 | 35 |
| Torsemide | Torsemide | 248 | 41 |
| Nifedipine Er | Nifedipine | 244 | 62 |
| Montelukast Sodium | Montelukast Sodium | 234 | 24 |
| Midodrine Hcl | Midodrine Hcl | 221 | 32 |
| Memantine Hcl | Memantine Hcl | 216 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 211 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 64 |
| Quetiapine Fumarate | Quetiapine Fumarate | 203 | 23 |
| Metformin Hcl Er | Metformin Hcl | 192 | 55 |
| Famotidine | Famotidine | 188 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 185 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 37 |
| Glipizide Er | Glipizide | 180 | 46 |
| Xarelto | Rivaroxaban | 174 | 20 |
| Latanoprost | Latanoprost | 165 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 66 |
| Farxiga | Dapagliflozin Propanediol | 154 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 43 |
| Digoxin | Digoxin | 132 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 26 |
| Januvia | Sitagliptin Phosphate | 128 | 23 |
| Finasteride | Finasteride | 124 | 33 |
| Meclizine Hcl | Meclizine Hcl | 123 | 21 |
| Olanzapine | Olanzapine | 116 | suppressed |
| Spironolactone | Spironolactone | 116 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 27 |
| Trulicity | Dulaglutide | 93 | 23 |
| Entresto | Sacubitril/Valsartan | 91 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 89 | 38 |
| Clonidine Hcl | Clonidine Hcl | 88 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 61 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | suppressed |
| Ezetimibe | Ezetimibe | 86 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 22 |
| Cephalexin | Cephalexin | 84 | 52 |
| Enoxaparin Sodium | Enoxaparin Sodium | 83 | 16 |
| Warfarin Sodium | Warfarin Sodium | 83 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | suppressed |
| Sucralfate | Sucralfate | 74 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 73 | 32 |
| Amantadine | Amantadine Hcl | 72 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 71 | 12 |
| Enalapril Maleate | Enalapril Maleate | 70 | 18 |
| Heparin Sodium | Heparin Sodium,porcine | 70 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 55 |
| Alendronate Sodium | Alendronate Sodium | 67 | 24 |
| Bupropion Xl | Bupropion Hcl | 64 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 63 | 23 |
| Tradjenta | Linagliptin | 62 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Glipizide | Glipizide | 57 | suppressed |
| Meloxicam | Meloxicam | 57 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 16 |
| Chlorthalidone | Chlorthalidone | 54 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 54 | 14 |
| Steglatro | Ertugliflozin Pidolate | 53 | suppressed |
| Calcitriol | Calcitriol | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 11 |
| Felodipine Er | Felodipine | 52 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Calcium Acetate | Calcium Acetate | 51 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 51 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 23 |
| Brilinta | Ticagrelor | 50 | suppressed |
| Folic Acid | Folic Acid | 50 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 17 |
| Hydrocortisone | Hydrocortisone | 48 | 29 |
| Lovastatin | Lovastatin | 48 | suppressed |
| Ozempic | Semaglutide | 48 | 14 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 47 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 22 |
| Tramadol Hcl | Tramadol Hcl | 47 | 22 |
| Prednisone | Prednisone | 46 | 28 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Lactulose | Lactulose | 43 | 13 |
| Nystatin | Nystatin | 43 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Caplyta | Lumateperone Tosylate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 20 |
| Cholestyramine | Cholestyramine (With Sugar) | 37 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 35 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 34 | suppressed |
| Enulose | Lactulose | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | 12 |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 34 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 33 | 15 |
| Risperidone | Risperidone | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 32 | suppressed |
| Humalog | Insulin Lispro | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 11 |
| Colchicine | Colchicine | 30 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | 14 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Cefepime Hcl | Cefepime Hcl | 27 | suppressed |
| Procrit | Epoetin Alfa | 27 | suppressed |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Actemra | Tocilizumab | 26 | suppressed |
| Meropenem | Meropenem | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Acetylcysteine | Acetylcysteine | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 25 | 13 |
| Topiramate | Topiramate | 25 | suppressed |
| Trospium Chloride | Trospium Chloride | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nyamyc | Nystatin | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Metronidazole | Metronidazole | 12 | 12 |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $724.18 · 32 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, BREZTRI, CREON, ELIQUIS, FARXIGA, LINZESS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error